Tuesday, February 25, 2025 | 06:58 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Cadila Healthcare soars 31% in 2 days on USFDA nod for Perphenazine tablets

Zydus Cadila has received final approval from the United States Food and Drug Administration to market Perphenazine tablets USP, 2 mg, 4 mg, 8 mg and 16 mg

v
Premium

This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults

SI Reporter Mumbai
Shares of Cadila Healthcare  (Zydus Cadila) surged 17 per cent to Rs 367 on the BSE on Wednesday in intra-day trade. The company today said that it has initiated an accelerated research programme with multiple teams in India and Europe developing a vaccine for the novel coronavirus, 2019-nCoV (COVID-19) based on two approaches.

The company’s robust manufacturing facilities for producing recombinant antigens and measles containing vaccines would enable rapid ramping up of the production for both vaccine candidates, once the proof-of-concept is established, the company said on clarification on news report, COVID 19 - Cadila Healthcare claims to make

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in